GeneOne Announces Expansion into RNA Vaccines and Therapeutics

Share Article

GeneOne Announces that its Subsidiary, Industry Leading Plasmid DNA CMO VGXI, has Entered into an Exclusive License to Produce RNA Biotherapeutics

GeneOne Life Science
This agreement will enable GeneOne Life Science to leverage the design capabilities provided by the Research Institute and Cooke’s research team for development of new RNA vaccines and therapies.

GeneOne Life Science announced today that its subsidiary VGXI, an industry leading plasmid DNA contract manufacturer, has entered into an exclusive license with the Houston Methodist Research Institute to produce clinical grade RNA at VGXI in The Woodlands, Texas.

The Research Institute RNAcore, directed by professor and chair, John Cooke, MD, PhD, is a leader in RNA synthesis, generating RNA constructs including mRNA, modified mRNA (mmRNA), microRNA cassettes, and noncoding RNA for scientific and medical collaborators. In addition to manufacturing methods, the RNAcore has also developed exceptional technologies for improved stability of RNA products and enhanced delivery of nucleic acid based therapies.

This agreement will enable GeneOne Life Science to leverage the design capabilities provided by the Research Institute and Cooke’s research team for development of new RNA vaccines and therapies. Notably, the pairing of HMRI’s technological advancements with VGXI’s GMP manufacturing excellence will allow for general adoption of this rapidly growing field. Anticipating the agreement, VGXI is already nearing completion of a facility expansion that includes purpose-built GMP production areas for RNA synthesis. Technology transfer in support of these new services is expected to commence immediately.

“RNA vaccines and therapeutics are the future of nucleic acid based technologies,” stated Young K. Park, President and CEO of GeneOne. “This license agreement between VGXI and HMRI allows GeneOne’s expansion into RNA technology. Expansion into RNA technology will allow GeneOne maximal breadth to leverage the rapid expansion of nucleic acid therapeutics.”

Houston Methodist Hospital is ranked as one of the nation’s best hospitals and the #1 hospital in Texas by US News & World Report. The Houston Methodist central campus includes the flagship hospital and the Houston Methodist Research Institute, located in the heart of the Texas Medical Center, the largest medical center in the world. The Research Institute RNAcore began as a core group for the Progenitor Cell Biology Consortium of the National Heart, Lung, and Blood Institute, and is now also supported by the Cancer Prevention Research Institute of Texas, to further the development of cutting-edge RNA technologies. For more information, visit HMRI RNAcore.

VGXI, Inc. has over 15 years of experience and is a leading provider of manufacturing and development services for DNA vaccines and gene therapies. The company has a reputation of success in manufacturing DNA products under cGMP conditions for clinical trials in the US, EU, Asia, Canada, and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. VGXI, Inc. is a wholly-owned subsidiary CMO of GeneOne Life Science, Inc. To learn more or request a quote, visit VGXI.

GeneOne Life Science Inc. (“GeneOne” KOSPI: 011000) is an international DNA vaccine and product developer and leading contract manufacturer of DNA plasmid-based agents for pre-clinical and clinical trials for global companies and institutions. It researches and develops DNA vaccines and products to prevent and treat incurable diseases in South Korea and internationally. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne's wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world. For more information, visit GeneOne Life Science.

Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

James Kim
Visit website